OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

NCT01920945 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Difficult enrollment

Conditions

New Daily Persistent Headache

Interventions

DRUG: OnabotulinumtoxinA

Sponsor

St. Luke's-Roosevelt Hospital Center

Collaborators

[object Object]